Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Coming therapies: adefovir.

G Angarano1

  • 1University of Bari, Italy.

International Journal of Clinical Practice. Supplement
|January 6, 2000
PubMed
Summary

Adefovir dipivoxil offers potent antiviral effects and convenient once-daily dosing. L-carnitine supplementation is necessary due to reduced plasma levels, and the drug is effective for initial or salvage therapy in short treatment durations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peculiar clinical presentation of COVID-19 and predictors of mortality in the elderly: A multicentre retrospective cohort study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Splenic abscesses as a first manifestation of Crohn's disease: a case report.

BMC gastroenterology·2019
Same author

Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood-brain barrier damage.

Infection·2019
Same author

Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus.

European review for medical and pharmacological sciences·2018
Same author

Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy.

HIV medicine·2017
Same author

Letter: chronic hepatitis C genotype 3 infection - still a hurdle toward a direct-acting anti-viral-induced HCV cure?

Alimentary pharmacology & therapeutics·2017

Area of Science:

  • Pharmacology
  • Virology
  • Hepatology

Background:

  • Adefovir dipivoxil is an acyclic nucleotide phosphonate analogue with significant antiviral properties.
  • Its pharmacokinetic profile allows for once-daily administration, enhancing patient compliance.
  • Observed reductions in plasma L-carnitine levels necessitate supplementation.

Purpose of the Study:

  • To evaluate the efficacy and safety of adefovir dipivoxil in antiviral therapy.
  • To assess its role in both first-line and salvage treatment regimens.
  • To determine the necessity of L-carnitine supplementation during treatment.

Main Methods:

  • Clinical trials were conducted to assess the antiviral activity of adefovir dipivoxil.
  • Pharmacokinetic studies monitored drug levels and L-carnitine plasma concentrations.
  • Patient outcomes were evaluated for efficacy and tolerability in various treatment settings.

Main Results:

  • Adefovir dipivoxil demonstrated potent and sustained antiviral activity.
  • Once-daily dosing was feasible due to the drug's long half-life.
  • L-carnitine supplementation was required to counteract reduced plasma levels.
  • Clinical evidence supports its use as first-line therapy.
  • The drug showed efficacy against drug-resistant strains, indicating a role in salvage therapy.

Conclusions:

  • Adefovir dipivoxil is an effective antiviral agent suitable for first-line and salvage therapy.
  • Monitoring and supplementation of L-carnitine are crucial during adefovir dipivoxil treatment.
  • The drug is safe and well-tolerated for short-term use.

Related Experiment Videos